Skip to content
Peptide research

KPV

Also known as Alpha-MSH Fragment
Category
Immune & Defense
Administration routes
Injectable
Regulatory status
Not FDA-approved

A tripeptide fragment of the hormone alpha-MSH, marketed for gut and skin inflammation and mucosal healing. Its anti-inflammatory mechanism (blocking the NF-kB pathway) is characterized in cell and animal models, and no human clinical trials or safety studies have been completed. The FDA has stated it lacks human exposure and safety data. Most supply is unregulated research-grade product of uncertain purity, and it is not an approved drug in the US.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

KPV is a naturally occurring anti-inflammatory tripeptide (just three amino acids: lysine-proline-valine) derived from alpha-MSH, a hormone involved in skin pigmentation and immune regulation. Despite its tiny size, KPV retains most of the potent anti-inflammatory activity of the full parent hormone. Unlike alpha-MSH, KPV does not work through the melanocortin receptors but instead enters cells via a dedicated transporter (PepT1) and directly shuts down inflammatory signaling pathways inside the cell. It has generated particular interest for inflammatory bowel conditions.

How it works in the body

A tripeptide fragment from alpha-MSH (alpha-melanocyte-stimulating hormone). It enters cells and directly inhibits the NF-kB inflammatory pathway by preventing the p65 subunit from entering the nucleus. This broadly reduces inflammation in gut tissue, skin, and other organs without needing to bind a cell-surface receptor.

Research overview

KPV research is entirely preclinical as of 2026, with zero human clinical trials completed. The FDA has stated it has not identified any human exposure data on KPV. The evidence consists of cell studies and rodent colitis models. Key findings show that KPV suppresses two major inflammatory signaling pathways (NF-kB and MAPK) at very low concentrations. Notably, inflamed gut tissue naturally upregulates the PepT1 transporter that carries KPV into cells, making diseased tissue a preferential target — a compelling feature for potential oral therapy. In animal models of inflammatory bowel disease, oral KPV significantly reduced colon inflammation, prevented weight loss, and lowered pro-inflammatory markers. In one study, it rescued all animals from death in a severe colitis model. Advanced nanoparticle delivery systems have been developed to improve oral absorption and targeted delivery to the colon. Despite promising animal data, the complete absence of human studies means safety and efficacy in people remain unknown.

Who researches KPV?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People researching immune system support

    Studied for immune modulation, antiviral, or antimicrobial properties.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People researching GI and digestive health

    Studied for gastrointestinal protection, gut lining repair, or digestive support.

Important considerations for

  • Those with Active infection requiring immune response

    Moderate

    KPV's strong anti-inflammatory action via NF-kB suppression may impair immune defense during active infection.

  • Those with Organ transplant recipients

    Moderate

    Immune-modulating properties may interact with immunosuppressive regimens unpredictably.

  • Those who are pregnant or breastfeeding

    Absolute

    No reproductive safety data for this MSH-derived peptide.

Safety & interactions

Do not use if

  • Active infection requiring immune response

    Moderate

    KPV's strong anti-inflammatory action via NF-kB suppression may impair immune defense during active infection.

  • Organ transplant recipients

    Moderate

    Immune-modulating properties may interact with immunosuppressive regimens unpredictably.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data for this MSH-derived peptide.

How to read the ratings

Benefits
= confidence in the evidence: High Ā· Medium Ā· Low Ā· Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High Ā· Moderate Ā· Low Ā· Theoretical
Interactions
= direction with this peptide: Protective / Synergistic Ā· Caution Ā· Neutral

Risk summary(6)

Rated by level of concern

  • Zero human clinical trials or safety studies completed

    High

    Literature review (all primary KPV studies are preclinical); FDA 503A/PCAC KPV briefing document, released ahead of the July 23-24, 2026 PCAC meeting

  • FDA has explicitly stated it lacks human exposure/safety data on KPV

    High

    FDA 503A Bulk Drug Substances briefing document ahead of PCAC meeting, July 23-24, 2026 (Drug Topics; RAPS coverage; ECRI-ISMP compounded-peptide white paper, Apr 2026)

  • Theoretical immunosuppression risk

    Theoretical

    Mechanism-based (Dalmasso 2008 PMID 18061177; tolerance data from contact-hypersensitivity models)

  • Contraindicated in pregnancy, breastfeeding, cancer history

    Low

    Absence of reproductive/oncology human data; anti-tumorigenic mouse data (Viennois et al., Cell Mol Gastroenterol Hepatol 2016, PMID 27458604)

  • Research-grade products may have purity/contamination issues

    Moderate

    ECRI-ISMP White Paper on Compounded Peptide Products, Apr 2026; FDA compounded-peptide quality concerns

  • Long-term effects unknown

    Moderate

    Literature review (no long-term human KPV data)

Interaction summary(6)

Rated by direction with this peptide

  • Systemic immunosuppressants (corticosteroids, calcineurin inhibitors)

    CautionTheoretical

    KPV's NF-kB suppression and tolerance-inducing activity could theoretically add to systemic immunosuppression; no human interaction data exist.

    Mechanism-based (Dalmasso et al. 2008, PMID 18061177)

  • PepT1-substrate drugs (oral beta-lactam antibiotics, ACE inhibitors e.g. captopril, valacyclovir/valganciclovir)

    CautionTheoretical

    KPV is absorbed through the PepT1 transporter, so co-administration could compete for transport and alter absorption of either agent. (The named agents are all canonical PepT1 substrates.)

    PepT1-mediated KPV uptake, PMID 18061177 / PMC2431115

  • TNF-alpha inhibitors / IBD biologics (e.g. infliximab, adalimumab)

    SynergisticTheoretical

    Overlapping cytokine/NF-kB suppression could be additive in inflammatory bowel disease, with a parallel theoretical caution for excess immunosuppression to monitor.

    Mechanism-based (shared NF-kB/cytokine pathway; PMID 18061177)

  • Oral 5-aminosalicylates (mesalamine, sulfasalazine)

    SynergisticTheoretical

    Both reduce intestinal NF-kB-driven inflammation, suggesting a theoretical additive gut anti-inflammatory effect rather than a harmful interaction.

    Mechanism-based (colitis-model anti-inflammatory activity, PMID 18061177)

  • Live attenuated vaccines

    CautionTheoretical

    By analogy to other immunomodulators, KPV's tolerogenic/anti-inflammatory effects could theoretically blunt vaccine response; not demonstrated for KPV.

    Mechanism/class analogy (no KPV-specific data)

  • Active chemotherapy / cytotoxic cancer therapy

    CautionTheoretical

    Effects of KPV immunomodulation during active oncologic treatment are uncharacterized in humans; direction is uncertain, warranting caution despite anti-tumorigenic signals in a mouse colitis-associated cancer model.

    Mechanism-based; anti-tumorigenic mouse data (Viennois et al., Cell Mol Gastroenterol Hepatol 2016, PMID 27458604)

Known risks(7)

  • Zero human clinical trials or safety studies completed

  • FDA has explicitly stated it lacks human exposure/safety data on KPV

  • Theoretical immunosuppression risk — may impair immune response to infections

  • Contraindicated in pregnancy, breastfeeding, and individuals with cancer history

  • Unregulated products sold online may have purity/contamination issues

  • Long-term effects completely unknown — no chronic exposure data in any species

  • Potential for additive immunosuppression if combined with immunosuppressive medications

Drug interactions(5)

  • Immunosuppressants (e.g., tacrolimus, cyclosporine, methotrexate)

    Theoretical additive immunosuppression. KPV inhibits NF-kB which is also a target of many immunosuppressants. No clinical interaction data exists.

  • NSAIDs (e.g., ibuprofen, naproxen)

    Both reduce inflammation through different mechanisms. Combined effects on gut mucosa are unstudied.

  • Biologic DMARDs (e.g., infliximab, adalimumab)

    Anti-TNF biologics and KPV both suppress TNF-alpha. Combining may produce excessive immunosuppression. Not studied.

  • Corticosteroids

    Both suppress NF-kB-mediated inflammation. Additive immunosuppression possible. No interaction data.

  • BPC-157

    Both target gut healing through different mechanisms. BPC-157 promotes angiogenesis, KPV suppresses NF-kB. Used together in some clinical protocols.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
25
Human Studies
0

100% of evidence is from cell culture and animal models. No human safety, pharmacokinetic, or efficacy data exists. FDA has stated it lacks human exposure data on KPV. Multiple rodent colitis models show consistent anti-inflammatory efficacy.

Researched for(7)

Rated by confidence in the evidence

  • Intestinal anti-inflammatory activity

    Medium

    Mouse colitis models show reduced colonic inflammation and tissue damage.

    Dalmasso et al., Gastroenterology 2008, PMID 18061177 / PMC2431115

  • NF-kB pathway inhibition

    Medium

    Blocks NF-kB and MAPK inflammatory signaling at nanomolar concentrations in cell studies.

    Dalmasso et al., Gastroenterology 2008, PMID 18061177; Kannengiesser et al., Inflamm Bowel Dis 2008, PMID 18092346

  • Pro-inflammatory cytokine reduction

    Medium

    Lowers IL-1beta, IL-6, TNF-alpha, and IFN-gamma while sparing anti-inflammatory IL-10.

    Dalmasso et al., Gastroenterology 2008, PMID 18061177 / PMC2431115

  • Targeted uptake via PepT1 transporter

    Medium

    Enters cells via PepT1, which rises in inflamed IBD tissue, concentrating it where needed.

    Dalmasso et al., Gastroenterology 2008, PMID 18061177 / PMC2431115

  • Antimicrobial properties

    Speculative

    Alpha-MSH peptides including KPV show antimicrobial activity in early lab work.

    Cutuli et al., J Leukoc Biol 2000;67(2):233-239, PMID 10670585

  • Skin inflammation reduction

    Low

    Preliminary animal and cell studies suggest anti-inflammatory effects on skin.

    Contact-hypersensitivity/tolerance mouse data (Brzoska & Luger melanocortin studies); KPV keratinocyte MAPK/NF-kB suppression (Lysine-Proline-Valine fine-dust keratinocyte study, 2025).

  • Mucosal healing acceleration

    Low

    A single colitis study reported reduced mucosal damage alongside lower inflammation.

    Dalmasso et al., Gastroenterology 2008, PMID 18061177 (reduced mucosal damage in DSS/TNBS colitis)

Benefits(7)

  • Intestinal anti-inflammatory activity

  • NF-kB pathway inhibition

  • Pro-inflammatory cytokine reduction

  • Targeted uptake via PepT1 transporter

  • Antimicrobial properties

  • Skin inflammation reduction

  • Mucosal healing acceleration

Key studies(5)

  1. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation

    Preclinical (in vitro + in vivo)5-10 mice per group8 days (DSS model), 48 hours (TNBS model)

    Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D

    Gastroenterology

    2008

    KPV transported by PepT1 into intestinal epithelial and immune cells. Nanomolar KPV inhibits NF-kB and MAPK. Oral KPV reduced MPO ~50% in DSS colitis and ~30% in TNBS colitis. Mechanism independent of melanocortin receptors.

  2. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease

    Preclinical (in vivo)Multiple groups of miceVariable (DSS and transfer colitis models)

    Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T

    Inflammatory Bowel Diseases

    2008

    KPV led to earlier recovery and significantly stronger weight regain in DSS colitis. Reduced inflammatory infiltrates and MPO. In MC1R-deficient mice, KPV rescued all animals from DSS colitis death.

  3. Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D

    Molecular Therapy

    2017

    HA-coated KPV nanoparticles (~272nm) achieved targeted colonic delivery. Oral HA-KPV-NPs showed stronger capacity to prevent mucosa damage and downregulate TNF-alpha vs. uncoated nanoparticles. Nontoxic and biocompatible.

  4. Getting SJ, Schiƶth HB, Perretti M

    Journal of Pharmacology and Experimental Therapeutics

    2003

    KPV anti-inflammatory effect is clearly different from core MSH peptides. KPV unlikely to act through melanocortin receptors, more likely acts through inhibition of IL-1beta functions.

  5. Singh M, Mukhopadhyay K

    BioMed Research International

    2014

    Comprehensive review of alpha-MSH and derivative peptides including KPV as anti-inflammatory and antimicrobial agents. KPV retains anti-inflammatory properties of full-length alpha-MSH.

What research suggests over time

  • Weeks 2-4

    Preclinical only

    No human dosing-trial data. Preclinical models show anti-inflammatory effects on gut tissue within days of oral or IP dosing.

  • Months 2-3

    Preclinical (mouse colitis)

    Earlier recovery and stronger weight regain vs vehicle in DSS colitis mice; reduced inflammatory infiltrates (Inflamm Bowel Dis 2008).

  • Long-term

    Preclinical only

    100% preclinical evidence base; no human safety, PK, or efficacy data. Placed on FDA Category 2 in 2023 (withdrawn in April 2026); in a draft interim policy posted October 28, 2026 and open for public comment until mid-November, HHS said it does not intend to act against limited oral and topical compounding under conditions.

Regulation & availability

Why researchers look at it

Inflamed gut tissue naturally upregulates the transporter (PepT1) that carries KPV into cells, creating a built-in targeting system where diseased tissue preferentially absorbs the peptide — and animal colitis models showed it rescued all subjects from death. Despite these striking preclinical results, the FDA has stated it has identified no human exposure data on KPV.

Estimated cost
No approved product and no verified reference price
FDA status
Not FDA-approved. KPV was placed in 503A Category 2 in 2023; its nomination was subsequently withdrawn. It is not in current Category 1 or on the final 503A bulks list. FDA's 2026 review found no human exposure studies. FDA's Pharmacy Compounding Advisory Committee reviewed it in July 2026; FDA's drug reviewers recommended against listing it and the committee voted in favor, as HHS's October 2026 policy records; FDA has not posted minutes or changed the list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound KPV acetate for an individual patient's prescription under conditions that include: a single-ingredient oral or topical product (not an injection) made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it.
WADA status
Not individually named in the 2026 List. S0 prohibits pharmacological substances without current governmental approval anywhere for human therapeutic use, unless covered elsewhere in the List. Athletes should confirm KPV's compound-specific status with their anti-doping organization.
Prescribability
KPV is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound KPV acetate for an individual patient's prescription under conditions that include: a single-ingredient oral or topical product (not an injection) made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing KPV; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.
Availability
Not available as an FDA-approved medicine. KPV is absent from current 503A Category 1 and the final 503A bulks list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound KPV acetate for an individual patient's prescription under conditions that include: a single-ingredient oral or topical product (not an injection) made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. Injectable KPV is outside the policy. Unregulated products sold online carry quality and safety risks.

International status

  • EU

    Not approved

  • US

    KPV is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound KPV acetate for an individual patient's prescription under conditions that include: a single-ingredient oral or topical product (not an injection) made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing KPV; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.

  • Australia

    Not approved

Regulatory timeline(5)

  1. 2003
    Early mechanistic researchGetting et al. report that KPV has anti-inflammatory effects distinct from core MSH peptides and is unlikely to act through melanocortin receptors.
  2. 2008
    Key preclinical studies publishedDalmasso et al. (Gastroenterology) and Kannengiesser et al. (IBD) establish PepT1-mediated mechanism and efficacy in colitis models.
  3. 2017
    Nanoparticle delivery advanceXiao et al. develop HA-functionalized KPV nanoparticles for targeted oral delivery to inflamed colon.
  4. 2023-09
    FDA Category 2 restrictionKPV placed on Category 2 list, restricted from compounding pharmacies due to lack of human safety data.
  5. 2026-10-28
    HHS draft interim compounding policyHHS posts a draft interim, non-binding enforcement-discretion policy covering 503A compounding of KPV acetate under conditions (Federal Register Doc. 2026-22192, scheduled for Federal Register publication October 30, 2026; open for public comment until mid-November). Not an approval; not added to the 503A bulks list.

Sources & FAQs

Research sources(6)

Frequently asked questions(6)

What is KPV?

KPV is a three-amino-acid peptide (lysine-proline-valine) derived from the tail end of alpha-MSH, a natural hormone involved in immune regulation. It has potent anti-inflammatory properties at very low concentrations.

Is KPV safe?

Unknown. There are zero human clinical trials or safety studies. Animal studies report no adverse effects, but the FDA has stated it lacks human exposure data. Theoretical concerns include immunosuppression. Pregnant/breastfeeding women and those with cancer history should avoid it.

How is KPV administered?

KPV can be administered subcutaneously (injection), orally, or topically. Oral KPV may leverage the PepT1 transporter for absorption, which is upregulated in inflamed gut tissue. Advanced nanoparticle oral delivery systems are being researched.

Can I legally obtain KPV in 2026?

KPV is not FDA-approved and is absent from current Category 1 and the final 503A bulks list. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound KPV acetate for an individual patient's prescription under conditions that include: a single-ingredient oral or topical product (not an injection) made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. Injectable KPV and unregulated products sold online are outside the policy.

Does KPV help with IBD or gut issues?

In animal models, KPV significantly reduces intestinal inflammation in colitis. However, there are no human trials confirming efficacy in IBD, Crohn's, or ulcerative colitis. Anecdotal reports from clinical use exist but are not published.

How does KPV differ from alpha-MSH?

KPV is just 3 amino acids from the C-terminal end of the 13-amino-acid alpha-MSH. Unlike alpha-MSH, KPV does not bind melanocortin receptors. Instead, it enters cells via the PepT1 transporter and directly inhibits NF-kB signaling. It retains anti-inflammatory activity without melanotropic effects.